For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220331:nRSe8475Ga&default-theme=true
RNS Number : 8475G Diaceutics PLC 31 March 2022
31 March 2022
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), the diagnostic
commercialisation company has been notified that on 28 March 2022, Yorkshire
Building Society have purchased ordinary shares ("Shares") on behalf of Stefan
Macdonald (PDMR), in respect of his purchase of Shares pursuant to the
Company's UK and Global Share Incentive Plan ("the SIP Schemes") for
employees. These purchases will be made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases
with a matched share award over an equivalent number of Shares purchased by
the employee, in the proportion of 2:1.
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Stefan Macdonald
2 Reason for notification
a. Position/Status Chief Growth Officer and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
108.00 p 139
Matched share award:
Price(s) Volume(s)
108.00 p 278
e. Date of the transaction Share purchase and Matched Share award: 28 March 2022
f. Place of the transaction Share Purchase and Matched Share Award: AIM Market of the London Stock
Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBKDBNABKDPNN